A Phase II Study of Chemo-Immunotherapy Followed by Durvalumab (MEDI4736) and Ceralasertib (AZD6738) in Treatment Naïve Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC) Big Ten Cancer Research Consortium BTCRC-LUN18-363
Muhammad Furqan
Summary
The primary objective of this single arm study is to estimate the progression free survival of previously-untreated patients with extensive stage small cell lung cancer. Patients will receive initial chemo-immunotherapy followed by maintenance therapy with durvalumab and oral ceralasertib.
Eligibility
- Age range
- 18+ years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: * Written informed consent and HIPAA authorization for release of personal health information. NOTE: HIPAA authorization may be included in the informed consent or obtained separately. * Age \>= 18 years at the time of consent. * ECOG Performance Status of 0-1 within 14 days prior to registration (Appendix A of Protocol). * Histological or cytological confirmed small cell lung carcinoma * Extensive stage disease * Patient must be considered suitable to receive a platinum-based chemotherapy as 1st line treatment for ES-SCLC. Chemotherapy must contain either Carboplatin or C…
Interventions
- DrugCisplatin
Cisplatin
- DrugCarboplatin
Carboplatin
- DrugEtoposide
Etoposide
- DrugDurvalumab
Durvalumab
- DrugCeralasertib
Ceralasertib
Locations (5)
- University of Illinois Medical CenterChicago, Illinois
- Indiana University Melvin and Bren Simon Comprehensive Cancer CenterIndianapolis, Indiana
- University of Iowa Hospitals and ClinicsIowa City, Iowa
- University of MarylandBaltimore, Maryland
- Ohio State University Comprehensive Cancer CenterColumbus, Ohio